Quanterix Taps Exact Sciences Executive as CCO to Drive Diagnostics Push
Event summary
- Jim Gute appointed Chief Commercial Officer of Quanterix on August 10, 2026.
- Gute previously served as Senior Vice President at Exact Sciences and President of GE Healthcare.
- Appointment aims to accelerate growth in diagnostics and core business segments.
- Quanterix focuses on ultra-sensitive protein detection and spatial analysis technologies.
The big picture
Quanterix's appointment of Jim Gute as CCO signals a strategic push into diagnostics, building on its precision biomarker science platform. The move comes amid industry trends toward earlier disease detection and personalized medicine, with Exact Sciences' recent acquisition by Abbott highlighting the value of commercial leadership in scaling diagnostic technologies. Quanterix aims to capitalize on its ultra-sensitive protein-detection and spatial analysis capabilities to expand its market reach.
What we're watching
- Diagnostics Expansion
- How Quanterix will leverage Gute's experience to penetrate the diagnostics market.
- Commercial Execution
- Whether Gute can re-energize commercial activities and drive growth across the business.
- Alzheimer's Focus
- The pace at which Quanterix advances its biomarker testing capabilities in critical disease markets like Alzheimer's.
Related topics